<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055731</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-12 - UC-0160/0203</org_study_id>
    <secondary_id>CDR0000270970</secondary_id>
    <secondary_id>EU-20238</secondary_id>
    <nct_id>NCT00055731</nct_id>
  </id_info>
  <brief_title>Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse</brief_title>
  <official_title>Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as
      nilutamide, bicalutamide, flutamide, or cyproterone may stop the adrenal glands from
      producing androgens. Drugs used in chemotherapy use different ways to stop tumor cells from
      dividing so they stop growing or die. It is not yet known whether hormone therapy is more
      effective with or without chemotherapy in treating prostate cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy with or
      without docetaxel and estramustine in treating patients who have prostate cancer that is
      locally advanced or at high risk of relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the 8-year survival rate, in terms of clinical and biological remission, of
           patients with locally advanced prostate cancer or with a high risk of relapse treated
           with neoadjuvant releasing factor agonist therapy and antiandrogen therapy with or
           without docetaxel and estramustine given before local radiotherapy or prostatectomy.

        -  Compare the prostate-specific antigen level at 3 months in patients treated with these
           regimens.

        -  Compare cancer progression by ultrasound in patients treated with these regimens.

        -  Compare survival without clinical remission of patients treated with these regimens.

        -  Compare the overall survival of patients treated with these regimens.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      Gleason score (7 or under vs over 7), T stage (T1 or T2 vs T3 or T4), prostate-specific
      antigen level (20 ng/mL or less vs greater than 20 ng/mL), and lymph node involvement (N0 vs
      N1 or N2). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral antiandrogen therapy comprising nilutamide twice daily or
           bicalutamide once daily or flutamide 3 times daily or cyproterone 4 times daily.
           Patients also receive docetaxel IV over 1 hour on day 2 and estramustine on days 1-5.
           Treatment repeats every 21 days for a total of 4 courses. Patients also receive
           luteinizing hormone-releasing hormone (LHRH) therapy IV comprising buserelin
           subcutaneously (SC) every 2 months or triptorelin, leuprolide, or goserelin SC every 3
           months.

        -  Arm II: Patients receive antiandrogen and LHRH therapy as in arm I. Beginning
           approximately 21 days after chemotherapy is completed, patients with N0 disease undergo
           radiotherapy 5 days a week for 6-7 weeks or radical prostatectomy. Patients with N1 or
           N2 disease undergo radiotherapy or no further local treatment.

      Hormonal therapy continues in both arms for 3 years in the absence of disease progression or
      unacceptable toxicity.

      Quality of life is assessed at baseline, at 3 months, and at 1 year.

      Patients are followed every 6 months for 5 years.

      PROJECTED ACCRUAL: A total of 250 patients (125 per treatment arm) will be accrued for this
      study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2002</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate, in terms of clinical and biological remission at 8 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate-specific antigen level at 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer progression as measured by ultrasound</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival without clinical remission</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buserelin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyproterone acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Locally advanced disease or at high risk for relapse

          -  No clinically or radiologically suspected metastases

          -  Prior lymphadenectomy required

          -  Meets at least 1 of the following criteria for poor prognosis:

               -  Gleason score greater than 7

               -  T3 or T4 disease

               -  Prostate-specific antigen greater than 20 ng/mL

               -  N1 disease

        PATIENT CHARACTERISTICS:

        Age

          -  Under 80

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  More than 10 years

        Hematopoietic

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  AST and ALT no greater than 1.5 times upper limit of normal (ULN)

          -  Bilirubin no greater than ULN

        Renal

          -  Creatinine less than 1.6 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular

          -  No uncontrolled or severe cardiovascular disease

          -  No prior thrombosis

        Pulmonary

          -  No prior pulmonary embolus

        Other

          -  No active infection

          -  No intolerance to aspirin

          -  No other prior malignancy except basal cell skin cancer

          -  No physical or psychological condition that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunotherapy

        Chemotherapy

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No prior hormonal therapy

          -  No other concurrent hormonal therapy

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

        Other

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Fizazi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Ambroise Pare</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique du Parc</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique des Quatre Pavillons</name>
      <address>
        <city>Lormont</city>
        <zip>33310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame de Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Clinique Claude Bernard</name>
      <address>
        <city>Metz</city>
        <zip>57072</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General de Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lapeyronie-CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>02</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix St. Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24.</citation>
    <PMID>22119204</PMID>
  </results_reference>
  <results_reference>
    <citation>Fizazi K, Lesaunier F, Delva R, et al.: A phase III trial of docetaxel-estramustine in high-risk localized prostate cancer (GETUG 12 trial): design, tolerance, response, and quality of life (QOL). [Abstract] 2010 Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, California. A-7, 2010.</citation>
  </results_reference>
  <results_reference>
    <citation>Fizazi K, Gravis G, Culine S: The GETUG 12 trial, a phase III randomized trial of docetaxel-estramustine in high-risk localized prostate cancer: clinical design and current status. [Abstract] 2006 Prostate Cancer Symposium, February 24-26, 2006, San Francisco, CA. A-153, 2006.</citation>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Nilutamide</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Estramustine</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Buserelin</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

